Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05287867 · ClinicalTrials.gov registry record · NA

Trial for Treating Painful Degenerative Disc Disease

A NA study of Degenerative Disc Disease, sponsored by Regenexx.

Recruiting
Registry status
NA
Development phase
42
Enrollment target
2
Study locations

NCT05287867: Recruiting NA study of Degenerative Disc Disease, sponsored by Regenexx.

NCT05287867 is a NA study of Degenerative Disc Disease that is actively recruiting participants, run by Regenexx. The registered enrollment target is 42 participants, below the 168-participant average among 42 other Degenerative Disc Disease trials with a reported enrollment target (75% lower). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05287867, a NA study of Degenerative Disc Disease, is actively recruiting participants, sponsored by Regenexx.

RECRUITING
Registry status
NA
Development phase
42 participants
Enrollment target
2
Study locations

Study Summary

To evaluate and compare two platelet-based treatments of the functional spinal unit spaced 4 weeks apart to sham procedures for the treatment of degenerative disc disease.

Primary Outcome

Difference in Numeric Pain Scale group differences (scale 0-10, where 0=no pain and 10=worst possible pain

Conditions Studied

Interventions

  • BIOLOGICAL Platelet-rich plasma (PRP), Platelet lysate (PL), and Platelet Poor Plasma (PPP)
  • OTHER Sham procedure

Study Locations (2)

Colorado

  • Centeno-Schultz Clinic - Broomfield
  • Centeno-Schultz Clinic - Lone Tree

Trial Details

FieldValue
Enrollment Target 42 participants
Start Date 2022-05-06
Est. Completion 2026-12-31
Phase NA
Regenexx

13 total trials

What NCT05287867 shows while recruiting

NCT05287867 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 42 participants, a relatively small participant target, below the 168-participant average among 42 other Degenerative Disc Disease trials with a reported enrollment target (75% lower).

The record links to 1 condition, with Degenerative Disc Disease appearing as the primary indexed condition, and to 2 interventions - of which Platelet-rich plasma (PRP), Platelet lysate (PL), and Platelet Poor Plasma (PPP) is the first listed.

NCT05287867 reports a single indexed study location in Colorado.

Frequently Asked Questions

What is clinical trial NCT05287867 about?

NCT05287867 is a clinical study titled "Trial for Treating Painful Degenerative Disc Disease". To evaluate and compare two platelet-based treatments of the functional spinal unit spaced 4 weeks apart to sham procedures for the treatment of degenerative disc disease.

What is the current status of trial NCT05287867?

This trial is currently recruiting. It is a NA study. The enrollment target is 42 participants. The study started on 2022-05-06. Estimated completion is 2026-12-31.

What conditions does trial NCT05287867 study?

This clinical trial studies the following conditions: Degenerative Disc Disease.

What interventions are being tested in trial NCT05287867?

The interventions under investigation include: Platelet-rich plasma (PRP), Platelet lysate (PL), and Platelet Poor Plasma (PPP) (BIOLOGICAL), Sham procedure (OTHER).

Who is sponsoring clinical trial NCT05287867?

This trial is sponsored by Regenexx, which has 13 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05287867 being conducted?

This trial has 2 study locations across Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Degenerative Disc Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT05287867's enrollment target sits among peer trials

42 32nd of 42 higher than 11 of 42 other Degenerative Disc Disease trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Degenerative Disc Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02852213 · 42 participants · Phase 1

    A Single-Stage, Adaptive, Open-label, Dose Escalation Safety and Efficacy Study of AADC Deficiency in Pediatric Patients

  • NCT03136146 · 42 participants · Phase 2

    Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Burkitt Lymphoma/Leukemia, or Double-Hit Lymphoma/Leukemia

  • NCT03178149 · 42 participants · Phase 1

    A Study of the Safety and Tolerability of ASP7317 in Senior Adults Who Are Losing Their Clear, Sharp Central Vision Due to Geographic Atrophy Secondary to Dry Age-related Macular Degeneration

  • NCT03663530 · 42 participants · NA

    Circadian Misalignment and Energy Balance

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT05287867, the US trial registry maintained by the National Library of Medicine. NCT05287867 (small enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.